drugset / Trial / NCT07241065

A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants

NCT07241065

Phase 1 Recruiting 42 enrolled AstraZeneca Parexel · collab
NaSequentialOpen-labelOther

Summary

The purpose of this study is to assess the effect of capivasertib on the pharmacokinetics of oral dextromethorphan in healthy participants.

Timeline

Start
2026-03-19
Primary completion
2026-06-17
Completion
2026-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Capivasertib Small molecule Oral
Subject Dextromethorphan Unknown Oral

Indications

No indication recorded.